Xeno Tech Labs

XenoTech (now part of BioIVT) specializes in nonclinical in vitro ADME/DMPK/DDI testing services for pharmaceutical and biotech companies to support regulatory submissions and advance drug development[2][3][7][8]. XenoTech, now operating as part of BioIVT following its acquisition in 2022, is a leading global Contract Research Organization specializing in nonclinical ADME/DMPK/DDI testing services. Founded in Kansas City, Kansas, in 1994 by Dr. Andrew Parkinson out of the University of Kansas Medical Center's expertise on xenobiotics, it grew rapidly as an expert partner for pharmaceutical and biotech companies seeking reliable preclinical data on drug metabolism and safety[2][7]. The company was previously acquired by SEKISUI Chemical in 2008 before joining BioIVT.

XenoTech does not develop its own therapeutics but instead provides critical laboratory services that help clients advance their drugs through regulatory approval processes worldwide. Its offerings include high-quality analytical chemistry tools and resources tailored to meet stringent FDA/global standards[4]. The company’s work underpins many IND/NDA submissions globally.

The main headquarters remains at Kansas City with strong ties to partner labs internationally—including Japan’s Drug Development Solutions Center—with no public trading symbol or financials available post-acquisition[7].

No evidence was found that “Xeno Tech Labs” refers to any other active life science/biotech/pharma/healthcare entity besides this well-established CRO.

If you meant another similarly named entity (“XENO Labs”, “XENO-Labs”, etc.), those refer either to sports supplement/anabolics companies or blockchain/metaverse ventures unrelated to healthcare/life sciences[5][6].